Sagact PLLC

1. AbbVie, Inc. $200,307 52 payments
2. Eli Lilly and Company $183,167 11 payments
3. Shire North American Group Inc $140,650 26 payments
4. Celgene Corporation $77,356 6 payments
5. Allergan Inc. $58,455 16 payments
6. Takeda Pharmaceuticals U.S.A., Inc. $53,191 36 payments
7. Boehringer Ingelheim Pharmaceuticals, Inc. $36,017 7 payments
8. Ironwood Pharmaceuticals, Inc $29,621 4 payments
9. Boehringer Ingelheim Pharma GmbH & Co.KG $17,451 8 payments
10. Boehringer Ingelheim International GmbH $12,498 1 payment

1. A Phase 2 Multicenter Randomized Parallel-Arm Placebo-Controlled Study of Ly3074828 in Subjects With Active Crohns Disease (Serenity) $102,931 3 payments
2. A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (Lucent 1) $56,255 2 payments
3. A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Shp647 As Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis Figaro UC 302 $52,403 7 payments
4. M14-675 $50,609 4 payments
5. (RPC01-3101) PhIII RPC1063 Induction and Maintenance in Moderate to Severe UC TRUENORTH (BMS Study Number: IM047-P22) (RPC01-3101) $38,184 2 payments
6. M14-234 $37,388 6 payments
7. Efficacy and Safety Study of Shp647 As Induction Therapy in Participants With Moderate to Severe Crohn's Disease $36,066 5 payments
8. M15-991 $32,647 6 payments
9. C3718-302 $29,621 4 payments
10. Proof of Clinical Principal in Crohn?s Disease $28,375 3 payments

1. Other $14,194 5 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.